Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA
| Autor: | Kaushik Pandit, Sujoy Ghosh, Pradip Mukhopadhyay, Purushottam Chatterjee, Prabhakar Pandey |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Linagliptin Risk Assessment CARMELINA Cardiovascular safety Diabetes mellitus Internal Medicine Humans Hypoglycemic Agents Medicine Intensive care medicine Glucose lowering Clinical Trials as Topic Dipeptidyl-Peptidase IV Inhibitors Evidence-Based Medicine business.industry Brief Report CAROLINA medicine.disease Indirect comparison Glimepiride Sulfonylurea Compounds Treatment Outcome Diabetes Mellitus Type 2 Cardiovascular Diseases Heart Disease Risk Factors glimipiride Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Diabetes & Vascular Disease Research |
| ISSN: | 1752-8984 1479-1641 |
| Popis: | Background: Despite having unquestionable glucose lowering efficacy, current guidelines no more favour the uses of sulphonylureas for CV safety concern, except when cost is an issue. However, formal cardiovascular outcome trial (CVOT) is not available. Materials and methods: We performed an indirect treatment comparison to find the hazard ratio for 3-point MACE, all-cause death, CV death and non-CV death between glimepiride and placebo based on two large CVOTs which established the CV safety of linagliptin (CARMELINA and CAROLINA). Results: Glimepiride was shown to have a non-inferior risk compared to placebo for 3-point MACE (HR 1.04, 95% CI 0.850, 1.274), all-cause mortality (HR 1.08, 95% CI 0.880, 1.317), CV death (HR 0.96, 95% CI 0.732, 1.259), and non-CV death (HR 1.24, 95% CI 0.893, 1.733). Conclusion: Cardiovascular safety of glimepiride is re-assuring and may help patients with type 2 diabetes world-over to avail the benefit of this affordable efficacious medication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|